{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:46:54Z","timestamp":1782798414555,"version":"3.54.5"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008353","name":"Funda\u00e7\u00e3o de Apoio ao Ensino, Pesquisa e Assist\u00eancia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To report the feasibility and short-term safety of off-label intravitreal eculizumab as a complement-inhibition strategy for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), based on two clinical cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case reports<\/jats:title>\n                    <jats:p>Two pseudophakic patients with progressive bilateral visual decline presented with GA and drusen in both eyes. Because this represents a novel, off-label therapeutic approach, intravitreal eculizumab was administered first in the worse-seeing eye in both cases, which also exhibited more advanced atrophic involvement. The treatment was selected as a potentially more accessible alternative to pegcetacoplan or avacincaptad pegol, which remain unavailable in Brazil. At fourmonth follow-up, no ocular toxicity was observed. There was no reduction in visual acuity in the treated eyes; in Case 1, BCVA improved from 20\/400 to 20\/200, while Case 2 maintained baseline acuity. Full-field electroretinography performed at baseline and at month 1 demonstrated preserved responses without reduction in B-wave amplitude, and multifocal electroretinography showed stable response densities with no amplitude loss.After functional assessment, structural multimodal imaging also showed no evidence of toxicity. Optical coherence tomography (OCT) revealed stable GA-related outer retinal atrophy without inner retinal changes, intra- or subretinal fluid, or any signs of acute retinal injury. Fundus autofluorescence and OCT angiography remained unchanged, with no findings of ocular inflammation, vascular compromise, or early acceleration of GA progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intravitreal eculizumab was feasible and demonstrated short-term safety in these two cases, with preserved visual function and no electrophysiological or structural evidence of toxicity. While biologically plausible as a C5-inhibition strategy, its therapeutic benefit remains unproven. Larger, controlled studies with extended follow-up are required to clarify long-term safety and efficacy in geographic atrophy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00842-1","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:49:26Z","timestamp":1775490566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Off-label intravitreal eculizumab for geographic atrophy: report of the first two cases"],"prefix":"10.1186","volume":"12","author":[{"given":"Rodrigo","family":"Jorge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo G. B.","family":"Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur S.","family":"Zupelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo T.","family":"Calado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"2","key":"842_CR1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","volume":"127","author":"DS Liao","year":"2020","unstructured":"Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology. 2020;127(2):186\u201395.","journal-title":"Ophthalmology"},{"issue":"1","key":"842_CR2","first-page":"1","volume":"130","author":"Apellis Pharmaceuticals","year":"2023","unstructured":"Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, et al.; OAKS and DERBY study investigators. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023;402(10411):1434\u201348.","journal-title":"Ophthalmology"},{"issue":"4","key":"842_CR3","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","volume":"128","author":"GJ Jaffe","year":"2021","unstructured":"Jaffe GJ, Westby K, Csaky KG, et al. C5 inhibitor avacincaptad pegol for geographic atrophy (GATHER1 trial). Ophthalmology. 2021;128(4):576\u201386.","journal-title":"Ophthalmology"},{"issue":"5","key":"842_CR4","first-page":"1","volume":"7","author":"Iveric Bio","year":"2023","unstructured":"Iveric Bio. GATHER2: Phase 3 avacincaptad pegol trial results. Ophthalmol Retina. 2023;7(5):1\u201310.","journal-title":"Ophthalmol Retina"},{"issue":"12","key":"842_CR5","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233\u201343.","journal-title":"N Engl J Med"},{"issue":"18","key":"842_CR6","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804\u201311.","journal-title":"Blood"},{"issue":"17\u201318","key":"842_CR7","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","volume":"33","author":"TC Thomas","year":"1996","unstructured":"Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33(17\u201318):1389\u2013401.","journal-title":"Mol Immunol"},{"issue":"11","key":"842_CR8","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of PNH. Nat Biotechnol. 2007;25(11):1256\u201364.","journal-title":"Nat Biotechnol"},{"key":"842_CR9","doi-asserted-by":"crossref","first-page":"100875","DOI":"10.1016\/j.preteyeres.2020.100875","volume":"80","author":"YC Kim","year":"2021","unstructured":"Cabrera FJ, Wang DC, Reddy K, Acharya G, Shin CS. Challenges and opportunities for drug delivery to the posterior of the eye. Drug Discov Today. 2019;24(8):1679\u201384.","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"842_CR10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ophtha.2013.09.044","volume":"121","author":"Z Yehoshua","year":"2014","unstructured":"B\u00fcssing D, Li Z, Li Y, et al. Pharmacokinetics of monoclonal antibodies and antibody fragments in the mouse eye following systemic administration. AAPS J. 2021;23:116.","journal-title":"Ophthalmology"}],"updated-by":[{"DOI":"10.1186\/s40942-026-00894-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000}}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00842-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00842-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00842-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:40:00Z","timestamp":1782798000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00842-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["842"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00842-1","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to update the references and to correct the ethical approval information.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40942-026-00894-3","URL":"https:\/\/doi.org\/10.1186\/s40942-026-00894-3","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that this study was approved by the Brazilian National Research Ethics Committee (Comiss\u00e3o Nacional de \u00c9tica em Pesquisa \u2013 CONEP), under CAAE number 87450325.1.0000.5440.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Meeting presentations"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}